Literature DB >> 6149126

Influence of intravenous beta-adrenergic blockade with or without partial agonist activity upon plasma cyclic AMP and catecholamines in healthy subjects.

C Gennari, G Pollavini, R Nami, G Francini, C Bianchini, P Verdecchia.   

Abstract

In a randomised within-subject double-blind study, 7 healthy male volunteers, aged 32 to 40 years, received at rest intravenous infusions of 2 mg propranolol (devoid of partial agonist activity), 2 mg oxprenolol (with partial agonist activity) and placebo. Cuff blood pressure did not vary after any of the 3 treatments. The heart rate did not change after placebo, but fell in the first 5 min both after propranolol and oxprenolol (p less than 0.01); the rate was slightly lower after propranolol than oxprenolol (p less than 0.05). The heart rate remained lower after both beta-blockers than placebo from 5 to 60 min after the infusion (both p less than 0.01), but the difference between the two beta-blockers was no longer significant. Plasma cyclic AMP showed a peak rise at 2 and 3 min after oxprenolol, and remained unchanged at those times after propranolol and placebo. From the 5th to the 60th min after infusion, the cyclic AMP concentration was lower after both beta-blockers than placebo, and with a slightly but not significantly higher level on oxprenolol than propranolol. Plasma noradrenaline and adrenaline were higher after the beta-blockers compared to placebo. Oxprenolol evoked a smaller and non-significant rise in both catecholamines. That oxprenolol, unlike propranolol, causes a sudden rise in plasma cyclic AMP soon after an i.v. infusion may be due to its partial agonist activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149126     DOI: 10.1007/bf00541927

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  10 in total

1.  Increases in plasma cyclic AMP dependent on endogenous catecholamines.

Authors:  S Kunitada; M Honma; M Ui
Journal:  Eur J Pharmacol       Date:  1978-03-15       Impact factor: 4.432

2.  The influence of beta blockers upon plasma cyclic AMP levels.

Authors:  J F England
Journal:  Aust N Z J Med       Date:  1980-04

3.  Cardio-circulatory effects of beta-adrenergic blockade in organic heart disease. Comparison between propranolol and CIBA 39,089-Ba.

Authors:  T Grandjean; J L Rivier
Journal:  Br Heart J       Date:  1968-01

4.  Differential effects of long-term cardioselective and nonselective beta-receptor blockade on plasma catecholamines during and after physical exercise in hypertensive patients.

Authors:  I W Franz; F W Lohmann; G Koch
Journal:  J Cardiovasc Pharmacol       Date:  1980 Jan-Feb       Impact factor: 3.105

5.  Beta-adrenoceptor blocking drugs and partial agonist activity. Is it clinically relevant?

Authors:  D G McDevitt
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

6.  Haemodynamic dose-response effects of intravenous beta-blocking drugs with different ancillary properties in patients with coronary heart disease.

Authors:  S H Taylor; B Silke; P S Lee; A Hilal
Journal:  Eur Heart J       Date:  1982-12       Impact factor: 29.983

7.  Partial agonist activity of practolol on human lymphocyte cyclic AMP production.

Authors:  D R Lima; P Turner
Journal:  Br J Clin Pharmacol       Date:  1981-05       Impact factor: 4.335

8.  Comparison of four different beta-adrenoceptor blocking drugs on lymphocyte isoprenaline-stimulated cyclic AMP production.

Authors:  D R Lima; S Kilfeather; A Hedges; P Turner
Journal:  Br J Clin Pharmacol       Date:  1981-06       Impact factor: 4.335

9.  Sources of cyclic nucleotides in plasma.

Authors:  R E Wehmann; L Blonde; A L Steiner
Journal:  J Clin Invest       Date:  1974-01       Impact factor: 14.808

10.  Specific refractoriness of adenylate cyclase in skin to epinephrine, prostaglandin E, histamine and AMP.

Authors:  K Adachi; H Iizuka; K M Halprin; V Levine
Journal:  Biochim Biophys Acta       Date:  1977-04-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.